A systematic review of health economic models and utility estimation methods in schizophrenia
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A systematic review of health economic models and utility estimation methods in schizophrenia
Authors
Keywords
-
Journal
Expert Review of Pharmacoeconomics & Outcomes Research
Volume 18, Issue 3, Pages 267-275
Publisher
Informa UK Limited
Online
2018-01-19
DOI
10.1080/14737167.2018.1430571
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone
- (2017) Bertalan Németh et al. Journal of Comparative Effectiveness Research
- Economic burden of schizophrenia: the European situation. A scientific literature review
- (2017) A Mancuso et al. EUROPEAN JOURNAL OF PUBLIC HEALTH
- Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis
- (2016) Liang Lin et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
- (2016) Sylvain Druais et al. PHARMACOECONOMICS
- The Societal Cost of Schizophrenia: A Systematic Review
- (2016) Huajie Jin et al. PHARMACOECONOMICS
- The Business Case for Expanded Clozapine Utilization
- (2016) Jessica L. Gören et al. PSYCHIATRIC SERVICES
- An evaluation of variation in published estimates of schizophrenia prevalence from 1990─2013: a systematic literature review
- (2015) Jason C. Simeone et al. BMC Psychiatry
- Scaling-up essential neuropsychiatric services in Ethiopia: a cost-effectiveness analysis
- (2015) Kirsten Bjerkreim Strand et al. HEALTH POLICY AND PLANNING
- A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda
- (2015) Solomon J. Lubinga et al. Applied Health Economics and Health Policy
- Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
- (2014) Tatiana Dilla et al. BMC Psychiatry
- Genesis of a complex disease
- (2014) Jonathan Flint et al. NATURE
- Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
- (2014) Taehwan Park et al. VALUE IN HEALTH
- Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options
- (2014) Pierre Chue et al. Neuropsychiatric Disease and Treatment
- Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis
- (2013) Fei-Li Zhao et al. PHARMACOECONOMICS
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
- (2013) Don Husereau et al. VALUE IN HEALTH
- A Square Peg in a Round Hole? Challenges with DALY-based “Burden of Disease” Calculations in Surgery and a Call for Alternative Metrics
- (2013) Richard Gosselin et al. WORLD JOURNAL OF SURGERY
- A Pharmacoeconomic analysis of compliance gains on antipsychotic medications
- (2013) Joep Damen et al. Applied Health Economics and Health Policy
- Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
- (2012) Eric D. A. Hermes et al. JOURNAL OF CLINICAL PSYCHIATRY
- Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score
- (2012) Helen Dakin et al. QUALITY OF LIFE RESEARCH
- A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence
- (2012) Carla Dias-Barbosa et al. Patient Preference and Adherence
- Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden
- (2012) Angelika Mehnert et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model
- (2011) Nicolas M. Furiak et al. CURRENT MEDICAL RESEARCH AND OPINION
- Health outcomes in economic evaluation: the QALY and utilities
- (2010) S. J. Whitehead et al. BRITISH MEDICAL BULLETIN
- A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss
- (2009) Maarten Treur et al. BMC HEALTH SERVICES RESEARCH
- Utility Assessment in Patients with Mental Disorders
- (2009) Hans-Helmut König et al. PHARMACOECONOMICS
- Schizophrenia, “just the facts” 4. Clinical features and conceptualization
- (2009) Rajiv Tandon et al. SCHIZOPHRENIA RESEARCH
- Cost-Effectiveness of Long-Acting Risperidone Injection versus Alternative Atypical Antipsychotic Agents in Patients with Schizophrenia in China
- (2009) Li Yang et al. VALUE IN HEALTH
- Avaliação econômica do tratamento da esquizofrenia com antipsicóticos no Sistema Único de Saúde
- (2009) Leandro Mendonça Lindner et al. REVISTA DE SAUDE PUBLICA
- Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK
- (2008) Andrew Davies et al. CURRENT MEDICAL RESEARCH AND OPINION
- Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation
- (2008) Andrew Briggs et al. Health and Quality of Life Outcomes
- Modelling Approaches
- (2008) Bart M S Heeg et al. PHARMACOECONOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now